Lawyers

David R. Bauer

Lawyers

Filters

Ocado Group acquisition of Kindred Systems

Davis Polk is advising Ocado Group plc on its acquisition of Kindred Systems, an advanced piece-picking robotics company, for approximately $262 million in cash, subject to typical purchase…

Biodesix $72 million IPO

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $72 million initial public offering by Biodesix, Inc. The common stock is listed on…

Abcam $180 million U.S. IPO of ADSs

Davis Polk advised the representatives of the several underwriters in connection with Abcam plc’s $180 million U.S. initial public offering of 10,287,000 American depositary shares…

Aligos Therapeutics $150 million IPO

Davis Polk advised  the representatives of the several underwriters in connection with the $150 million initial public offering of 10,000,000 shares of common stock of Aligos…

Royalty Pharma $728 million secondary offering

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $728 million secondary offering of 17,343,037 of its Class A ordinary shares by certain selling…

Aziyo Biologics $50 million IPO

Davis Polk advised the representatives of the several underwriters in connection with the $50 million initial public offering of common stock by Aziyo Biologics, Inc. The common stock…

Beam Therapeutics $127 million offering

Davis Polk advised the joint book-running managers in connection with an SEC-registered offering of 5,750,000 common shares of Beam Therapeutics Inc. for total gross proceeds of $127…

Gilead Sciences $7.25 billion senior notes offering

Davis Polk advised Gilead Sciences, Inc. in connection with an SEC-registered offering of $7.25 billion aggregate principal amount of senior notes, consisting of (i) $500 million aggregate…

ADC Therapeutics $204 million SEC-registered offering

 Davis Polk advised ADC Therapeutics SA on its SEC-registered offering of 6,000,000 common shares for total gross proceeds of $204 million. ADC Therapeutics is listed on the New York…
Back to top